drugset / Trial / NCT00181558

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

NCT00181558

RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread to the bones.

Timeline

Start
2001-12
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atrasentan Other / unclassified Oral
Subject Zoledronic acid Other / unclassified Intravenous